Trends in Molecular Medicine
ReviewAdvances in stem cell therapy against gliomas
Section snippets
Stem cell-based therapy against gliomas
Gliomas account for approximately 60% of all primary central nervous system (CNS) tumors with a very poor prognosis. Glioblastoma (GBM), the most malignant type of glioma, has a median survival of approximately 18–21 months 1, 2. The characteristics of this malignancy include uncontrolled cellular proliferation, invasiveness with both long root-like processes and single invasive cells, areas of necrosis, resistance to apoptosis, extensive angiogenesis, and multiple genetic alterations (Figure 1
Stem cells for cargo delivery
Genetic manipulation is one of the research strategies most often investigated for glioma, because it has an almost unlimited range of potential targets. Therapeutic genes stimulating the immune system, inducing tumor cell death, inhibiting angiogenesis, and limiting metastatic potential have been extensively studied, and many different approaches and gene combinations have been used (Box 2). However, gene therapy (and/or viral therapy) alone has not been able to live up to its full potential,
Routes of administration and enhancement of the stem cell model
Several studies have focused on developing alternative strategies to increase the therapeutic effect of stem cell-based therapy to brain tumors by enhancing delivery mode, tumor tropism, and cellular delivery vehicles (Table 1 and Box 2).
Glioma stem cell therapy in the clinic
Although a vast amount of interesting and exciting research is being explored using stem cells as a therapeutic strategy for malignant gliomas, most of these studies are being performed in the laboratory setting. This indicates that although the bench results are promising, translating this therapy to the clinic remains difficult with only a single clinical trial in progress (Box 3). At the City of Hope (California) by Aboody et al., NSCs (HB1.F3-CD) genetically modified to express Escherichia
Concluding remarks
Stem cells provide a highly promising and innovative approach for the treatment of malignant gliomas. Provided that some of the discussed issues/limitations can be addressed, this therapeutic strategy could become of tremendous value in the search for a cure for tumors as heterogeneous and as difficult to reach as glioblastoma. Other exciting strategies such as gene therapy and oncolytic viral therapy, which by themselves have failed to establish clinically relevant antitumor effects, are now
Acknowledgments
B.A.T. is supported by grants from the National Institutes of Health, the National Institute of Neurological Disorders and Stroke (1R01NS064983) and the National Cancer Institute (1R01CA166077). M.H.D. is supported by a Fulbright scholarship, the Saal van Zwanenberg Foundation, VSB fonds, Dr Hendrik Muller Vaderlandschfonds, the Dutch Cancer Foundation (KWF Kankerbestrijding), the Hersenstichting brain fund, as well as the Jo Keur (Leiden hospital). M.S.B. is supported by a Fulbright
References (91)
A perivascular niche for brain tumor stem cells
Cancer Cell
(2007)Radioresistant glioma stem cells – therapeutic obstacle or promising target?
DNA Repair (Amst.)
(2007)Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases
Mol. Ther.
(2009)Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma
Mol. Ther.
(2011)- et al.
Immunosuppression by mesenchymal stromal cells: from culture to clinic
Exp. Hematol.
(2008) - et al.
Human embryonic stem cells: a potential source for cellular therapy
Am. J. Transplant.
(2004) Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts
Cancer Lett.
(2011)Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma
Biochem. Biophys. Res. Commun.
(2012)Therapeutic effect of genetically modified human neural stem cells encoding cytosine deaminase on experimental glioma
Biochem. Biophys. Res. Commun.
(2012)hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence
Mol. Ther.
(2011)
Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas
Eur. J. Cancer
Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors
Biomaterials
Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy
Int. J. Pharm.
Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas
Mol. Ther.
CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas
Biochem. Biophys. Res. Commun.
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Blood
Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model
Neoplasia
Focus on central nervous system neoplasia
Cancer Cell
Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone
Neuron
Single adult human CD34+/Lin–/CD38– progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells
Blood
Conditional probability of long-term survival in glioblastoma: a population-based analysis
Cancer
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States
Clin. Cancer Res.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Genes Dev.
Assumptions in the radiotherapy of glioblastoma
Neurology
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas
Acta Neuropathol.
Identification of a cancer stem cell in human brain tumors
Cancer Res.
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
Cancer Res.
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas
Proc. Natl. Acad. Sci. U.S.A.
Development of a tumor-selective approach to treat metastatic cancer
PLoS ONE
The changing face of neural stem cell therapy in neurologic diseases
Arch. Neurol.
The therapeutic potential of mesenchymal stem cells. Cell- and tissue-based therapy
Expert Opin. Biol. Ther.
Why are MSCs therapeutic? New data: new insight
J. Pathol.
Embryonic stem cell differentiation: emergence of a new era in biology and medicine
Genes Dev.
Gene delivery by embryonic stem cells for malignant glioma therapy: hype or hope?
Cancer Biol. Ther.
Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells
Brain
VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells
Brain
A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy
Stem Cells
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
Proc. Natl. Acad. Sci. U.S.A.
Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy
Stem Cells
Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas
Nat. Neurosci.
A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models
Cancer Res.
Suicidal gene therapy in an NF-κB-controlled tumor environment as monitored by a secreted blood reporter
Gene Ther.
Functional drug screening assay reveals potential glioma therapeutics
Assay Drug Dev. Technol.
Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy
Cancer Res.
Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma
Neuro Oncol.
Cited by (0)
- *
These authors contributed equally.